MedTrace Logo

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-04-12

No results posted yet for this study

Summary

To determine whether CC-10004, a phosphodiesterase inhibitor, is useful in treating chronic cutaneous sarcoidosis.

Conditions

  • Sarcoidosis
  • Cutaneous Sarcoidosis

Interventions

DRUG

CC-100004

After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Medical University of South Carolina

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00794274 on ClinicalTrials.gov